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Abstract
Background: Azithromycin (AZM) is a macrolide antibiotic that displays an excellent safety profile even in children
and pregnant women and has been shown to have anti-malarial activity against blood stage Plasmodium
falciparum. This study evaluated the transmission-blocking effect of AZM using a rodent malaria model.
Methods: AZM-treated mice infected with Plasmodium berghei were exposed to Anopheles stephensi mosquitoes,
followed by the observation of parasite development at different phases in the mosquito, i.e., ookinetes in the
midgut, oocysts on the midgut, and sporozoites in the midgut and salivary glands. Furthermore, to evaluate the
effect on organelle replication of each stage, quantitative real-time PCR analysis was performed.
Results: The inhibitory effect of AZM was noticeable in both gametocyte-ookinete transformation in the midgut
and sporozoite production in the oocyst, while the latter was most remarkable among all the developmental
phases examined. Real-time PCR analysis revealed that AZM suppressed apicoplast replication at the period of
sporozoite production in oocysts.
Conclusions: AZM inhibits parasite development in the mosquito stage, probably through the same mechanism as
in the liver and blood stages. Such a multi-targeting anti-malarial, along with its safety, would be ideal for mass
drug administration in malaria control programmes.
Background
Malaria, caused by protozoan parasites of the genus
Plasmodium and transmitted by mosquitoes of the
genus Anopheles, remains one of the world’sm o s t
important health problems, causing nearly a million
deaths per year [1]. Because of the rapid emergence and
spread of drug-resistant Plasmodium falciparum,t h e
development of alternative control tools is needed
urgently [2]. A possible strategy is to block malarial
transmission from gametocyte carriers to the vector
mosquitoes using a transmission-blocking vaccine [2,3]
or a drug that interrupts parasite development in the
mosquito vector [4]. The strategy of blocking malarial
transmission has been claimed to limit the spread of
malaria and to reduce the spread of drug-resistant para-
sites [5-8].
Considering that very high coverage is essential for a
significant impact on malaria transmission, mass drug
administration (MDA) for people including children and
pregnant women in endemic area is required [6]. In
MDA, safety is a paramount issue because the drug will
be given to large numbers of non-infected individuals
[7]. Thus, only drugs with an excellent safety profile
should be considered for MDA. Primaquine, the gener-
ally available gametocytocidal drug, has been used pre-
viously in MDA [9,10], but its haemolytic effect in
glucose-6-phosphate dehydrogenase deficient individuals
has made this drug less acceptable for MDA [7,8]. To
date, a limited number of drugs or compounds has been
confirmed to possess transmission-blocking activity
[5,11-13]. Most of them have not been considered for
clinical applications due to their toxicity and/or cost of
development [12]. Therefore, if licensed antibiotics are
proven to have transmission-blocking activity, practical
evaluation should be greatly accelerated and their
impact should be fully exploited [14].
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been broadly used for the treatment of bacterial infec-
tions [15], displays a good safety profile, including in
children and pregnant women [2,16,17]. Importantly,
AZM was shown to have inhibitory activity against Plas-
modium spp. both in vitro and in vivo [15,18-20] and
was effective for prophylaxis and treatment against
human malaria in field conditions [21-23]. It has been
proposed that AZM exerts a “delayed death” effect
against blood stage P. falciparum,i nw h i c ht h ep r o g e n y
of AZM-treated parasites that inherited non-functional
apicoplasts fail to develop, leading to a delayed, but
potent anti-malarial effect [24]. Therefore, it was
hypothesized that this delayed effect of AZM would also
be exerted against parasite development in the mos-
quito, leading to transmission blockade.
The aim of this study was to evaluate the transmis-
sion-blocking activity of AZM using a rodent malaria
model, and to investigate whether the apicoplast is the
target of AZM in the mosquito stage.
Methods
Parasites and mosquitoes
Plasmodium berghei ANKA strain, clone 2.34 was main-
tained by cyclic passage in BALB/c mice (Japan SLC,
Shizuoka, Japan) and SDA500 strain of Anopheles ste-
phensi. For drug treatment and mosquito biting studies,
mice infected with the second blood passage parasites
after mosquito transmission were used. Cyclic colonies
of An. stephensi were maintained at University of Occu-
pational and Environmental Health, Japan. Mosquitoes
were reared according to the MR4 Methods in Ano-
pheles Research Manual [25].
Administration of AZM to P. berghei-infected mice
All the animal experiments were performed under the
control of the Ethics Committee of Animal Care and
Experimentation in accordance with The Guiding Prin-
ciples of Animal Care Experimentation, The University
of Occupational and Environmental Health, Japan and
the Japanese Law for Animal Welfare and Care (No.
221). Six-week-old female BALB/c mice (18.5-20.5 g)
were infected with P. berghei by intraperitoneal injection
of 5 × 10
6 parasitised erythrocytes per mouse. Parasitae-
mia and mature microgametocytaemia (density of male
gametocytes), the latter of which is thought to be a lim-
iting factor for the efficiency of fertilization in the vector
mosquito due to the female-biased sex ratio [26,27],
were monitored daily by microscopic observation of
Giemsa-stained thin blood smears [14]. Four days post-
infection, 6-10 infected mice were divided into two
groups to match parasitaemia and microgametocytae-
mia. Mice of the experimental group were given azithro-
mycin (AZM) (LKT Laboratories, St. Paul, MN, USA)
suspended in 0.3% carboxymethylcellulose (CMC)
(Nacalai Tesque, Kyoto, Japan) at a dose of 400 mg/kg
orally and those of the control group were given 0.3%
CMC only.
Exflagellation assay
In order to evaluate the effect of AZM on exflagellation
(microgametogenesis) activity, 3 μlo ft a i lb l o o dw a s
taken from each infected mouse at 24 hours after drug
administration (the same time as blood feeding). The
blood sample was immediately mixed with 300 μlo f
exflagellation medium (RPMI 1640 containing 25 mM
HEPES, 25 mM sodium bicarbonate, 20% foetal bovine
serum, pH 8.0) and 20 μl of the suspension was loaded
onto a Fuchs-Rosenthal haemocytometer (C-Chip DHC-
F01, Digital Bio Technology, Seoul, Korea), then incu-
bated at 19°C for 20 minutes. Exflagellation centres
were numerated by microscopic observation at ×200
magnifications and expressed as a number of exflagella-
tion events per 10
4 red blood cells (RBCs).
Assessment of sporogonic development
At 24 hours post-drug administration, infected mice
were exposed to 300-400 mosquitoes in each group that
had emerged 6-8 days before, for 15 minutes at 19°C.
Two- to three-hundred engorged mosquitoes in each
group were collected and kept at 19°C. At 24 hours post
blood feeding, 10-20 mosquitoes in each group were dis-
sected for ookinete counting. The gut contents of each
mosquito were mixed with fetal bovine serum on a glass
slide. A thin film of the midgut contents was prepared
and stained with Giemsa, then the ookinete count was
made in a total of 300 observation fields with ×50 oil-
immersion objective and ×10 ocular lens as described
previously [28]. At 10 days post blood feeding, 10-20
mosquitoes in each group were dissected and the num-
ber of oocysts per midgut was determined by light
microscopic observation. At 20 days post blood feeding,
30 mosquitoes in each group were dissected for sporo-
zoite numeration. Ten sets of salivary glands and mid-
guts were dissected out and pooled separately in 1.5 ml
microtubes, then homogenized in 100 μl PBS. The sus-
pension was loaded onto a haemocytometer, and the
number of sporozoites was determined. Three replicates
were performed for each experimental set. In another
set of experiment, 20 mosquitoes from each group were
individually dissected at 20 days post blood feeding, and
t h ep r e v a l e n c eo fs a l i v a r yg l a n ds p o r o z o i t e sw a s
examined.
Quantitative real-time PCR analysis to determine effect
of AZM on apicoplast DNA replication
In order to evaluate the effect of AZM-treatment on
apicoplast DNA replication, apicoplast DNA/nuclear
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PCR. Blood stage genomic DNA of P. berghei was pre-
pared from the mouse blood collected from 3-5 infected
mice by cardiac puncture at 24 or 72 hours post-drug
administration. For preparation of mosquito stage geno-
mic DNA, midguts were dissected out and pooled from
20 infected mosquitoes in each group at 5, 10, and 15
days post blood feeding. Genomic DNA was isolated
from the parasites by using Get pure DNA Kit-Cell, Tis-
sue (Dojindo Molecular Technologies, Kumamoto,
Japan) and Dr. GenTLE Precipitation Carrier (Takara
Bio, Shiga, Japan) in accordance with the manufacturer’s
instructions. The nuclear and organelle-specific genes
that we used for quantification of the nuclear DNA, api-
coplast DNA, and mitochondrial DNA were fabI, tufA,
and cytb, respectively [15,29]. Primers used for the
amplification of each gene were designed and checked
for specificity by using Primer-BLAST provided by
National Center for Biotechnology Information [30].
The accession numbers of each gene and the designed
primer sequences are listed in Additional file 1. Quanti-
tative PCR was performed using Fast Real-Time SYBR
Green master mix and a StepOnePlus sequence detec-
tion system (Applied Biosystems, Foster City, CA, USA)
in accordance with the manufacturer’s instructions. PCR
was performed in duplicate for each sample. DNA sam-
ples obtained from blood stage parasites in the control
group, which resulted in highest amount of amplified
product for each gene, were serially diluted and used as
the standard for absolute quantification. Organelle DNA
replication was evaluated by comparison of PCR product
quantities from organelle DNA with nuclear DNA
[31,32]. To confirm specific amplification of desired pro-
ducts, DNA melting curve analysis was performed.
Statistical analysis
Mann-Whitney U test was used to determine statistical
differences in parasite number, parasitaemia and micro-
gametocytaemia between the experimental and control
groups. P values lower than 0.05 were considered signifi-
cant. All tests were two-tailed. All statistical analyses
were performed using Microsoft Excel 2007 (Microsoft
Corporation, Tokyo, Japan).
Results
Determination of appropriate timing for blood feeding
It has already been reported that AZM exerts schizonto-
cidal effects against P. berghei blood stage four days
after drug administration [19]. Thus, to evaluate the
effect of AZM against mosquito stage, the earlier timing
seems to be appropriate for blood feeding. Therefore, at
first, the parasitaemia and microgametocytaemia were
checked at 24 hours post-drug administration. No sig-
nificant difference between AZM-treated mice and
control mice was observed in either parasitaemia (med-
i a nv a l u e :6 . 0 %i nA Z M - t r e a t e dm i c ev s5 . 7 %i nc o n t r o l
mice, P =0 . 7 2 ,n = 20) or microgametocytaemia
(0.031% vs 0.033%, P =0 . 8 9 ,n =2 0 ) .T h e n ,i tw a s
decided to treat mice with AZM 24 hours prior to
blood feeding.
Effect of AZM on exflagellation activity of P. berghei
microgametocytes
To evaluate the effect of AZM on the function of micro-
gametocyte, infected mouse blood was collected at the
time of blood feeding (24 hours post-drug administra-
tion) and used to test for exflagellation activity. No sig-
nificant difference of exflagellation events was observed
between AZM-treated mice and control mice, suggest-
ing that AZM did not affect the biological function of
male gametocytes (Figure 1).
Effect of AZM on mosquito stage development of
P. berghei
The effect of AZM on parasite development in An. ste-
phensi mosquitoes fed on blood of P. berghei-infected
mice that had been given AZM 24 hours before blood
feeding was assessed. Mosquitoes were dissected at
24 hours, 10, and 20 days post blood feeding to deter-
mine the levels of ookinetes, oocysts, and sporozoites
both in the midgut and salivary glands, respectively. This
Figure 1 Effect of AZM on exflagellation of P. berghei
microgametocytes in vitro. The number of exflagellation events
per 10
4 RBCs was counted in vitro 24 hours after administration of
AZM (White circle) or CMC (Black circle, as control). Horizontal lines
and adjacent numbers represent the median number of
exflagellation events in each group. P values were determined by
Mann-Whitney U test. Combined results of three independent
experiments are shown (n = 12).
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parasite development in all the four stages in the mos-
quito, i.e., reduction of ookinetes in the midgut (50%
reduction as compared with the controls, P = 0.016,
Figure 2A), oocysts on the midgut (45% reduction,
P = 0.003, Figure 2B), sporozoites both in the midgut
(79% reduction, P < 0.001, Figure 2C) and in the salivary
glands (50% reduction, P = 0.002, Figure 2D). In another
set of experiment, the prevalence of salivary gland sporo-
zoites was 100% in both groups, indicating that AZM did
not reduce the prevalence.
Effect of AZM on replication of P. berghei apicoplast
In the case of blood stages, inhibition of apicoplast repli-
cation by chemicals has been usually evaluated by the
ratio of apicoplast DNA to nuclear DNA [31,32]. In this
study, to evaluate the effect of AZM on the replication
of P. berghei apicoplast, the relative amounts of organel-
lar DNA to nuclear DNA were estimated using real-
time PCR. During the blood stage of parasite develop-
ment, AZM treatment resulted in the suppression of
apicoplast replication at 72 hours post-drug administra-
tion (1.0 at 24 hours post-drug administration, 0.14 at
72 hours post-drug administration, Figure 3A). This
result agreed with previous reports about the effect of
AZM [24], clindamycin [31], and 15-deoxyspergualin
[32] on P. falciparum in vitro, all of which are believed
to impair parasite growth by inhibiting apicoplast repli-
cation. In the mosquito stage, apicoplast replication in
parasites derived from AZM-treated mice was not
reduced at 5 days post blood feeding, i.e., 6 days post-
drug administration, followed by successive suppressions
Figure 2 Effect of AZM on P. berghei mosquito stage development. Mosquitoes were allowed to feed on blood of P. berghei-infected mice
that had been given AZM (White circle) or CMC (Black circle) at 24 hours before blood feeding. (A) Ookinete numbers in midguts dissected at
24 hours post blood feeding were determined by microscopy analysis. (B) Oocyst numbers on midguts dissected at 10 days post blood feeding
were counted. (C, D) Sporozoite numbers in midgut oocysts (C) and salivary glands (D) were determined at 20 days post blood feeding.
Horizontal lines and adjacent numbers represent the medians (n = 40 in (A); n = 60 in (B); n = 15 (calculated from 150 mosquitoes) in (C) and
(D)). P values were determined by Mann-Whitney U test. Combined results of three to five independent experiments are shown.
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In contrast, mitochondrial replication was not affected
in both the blood and mosquito stages (Figure 3A, B),
suggesting that the inhibitory effect of AZM was specific
to the apicoplast.
Discussion
It has been demonstrated that AZM inhibits apicoplast
replication in blood stage P. falciparum [24] and liver
stage P. berghei [33]. Indeed, combinations of AZM with
conventional schizontocides were applied for human
malaria cases in the field. They showed good results
[22,34,35], whereas AZM monotherapy did not [34]. In
this study, it was shown for the first time that AZM
inhibits apicoplast replication of P. berghei also in the
mosquito stage. These findings imply that AZM sup-
presses parasite growth at three different stages in the
life cycle by attacking the same target, apicoplast repli-
cation. These data indicate that AZM has a further pos-
sibility of blocking malaria transmission.
In the present study, P. berghei development was
apparently inhibited by AZM treatment at all the phases
examined. It is notable that AZM treatment suppressed
ookinete formation without affecting exflagellation
activity, implying that AZM affected only macrogameto-
cytes (female). This is compatible with the fact that the
apicoplast is a maternally inherited organelle [36,37].
Considering the continuous development of parasites
in mosquitoes, the reduction of oocysts (45%) was
similar to the reduction of ookinetes (50%), suggesting
that AZM does not have much effect on oocyst forma-
tion from ookinetes. On the other hand, the inhibitory
effect of AZM on the mosquito stage was most
remarkable in the production of sporozoites (79%). It
has been reported in both blood and liver stage schi-
zogony that replication and segregation of apicoplasts
proceed during the middle to late stages of serial
nuclear divisions and are completed before daughter
merozoites are formed [33,38]. These findings allow it
to be speculated that in the case of mosquito stage
sporogony, apicoplast replication occurs during middle
to late stage of nuclear divisions in oocysts, corre-
sponding to around 8 to 15 days post blood feeding
for oocyst maturation [39]. Therefore, inhibition of
sporozoite production may result from the inhibition
of apicoplast replication during the above-mentioned
period in oocysts. Taken together, it seems that AZM
inhibits mosquito stage development at two different
Figure 3 Effect of AZM on replication of P. berghei apicoplasts. Ratios of apicoplast DNA/nuclear DNA in AZM-treated parasites were
calculated by quantitative real-time PCR, then standardized with the ratio from control parasites, giving ratios of (apicoplast/nuclear DNA ratio in
AZM-treated parasites)/(apicoplast/nuclear DNA ratio in control parasites) (Black square). Similarly, the ratios of (mitochondrial/nuclear DNA ratio
in AZM-treated parasites)/(mitochondrial/nuclear DNA ratio in control parasites) were calculated (White square). (A) Analysis of blood stage
parasites at 24 hours post-drug administration (= the time of blood feeding) and 72 hours post-drug administration. (B) Analysis of mosquito
stage parasites at 5, 10, and 15 days post blood feeding. DNA ratio of each control group is 1.0 on the vertical axis. A representative result of
four independent experiments is shown.
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midgut and sporozoite production in the oocyst. The
latter is probably due to the inhibition of apicoplast
replication. Interestingly, the drastic impact observed
on midgut sporozoites was diminished at the salivary
gland phase. A possible explanation for this discre-
pancy could be in part attributable to a linear relation-
ship model in which the number of P. berghei salivary
gland sporozoite per individual An. stephensi mosquito
linearly related to the number of oocysts per mosquito
[40]. Although it describes better at low oocyst num-
bers (less than 50 per mosquito), according to this
model, 45% reduction in oocyst number corresponds
to 45% reduction in salivary gland sporozoites, match-
ing well with the pattern observed in the present
study. Therefore, the observed change in the reduction
rate of parasite number may not be relevant to pro-
longed impairment of apicoplast replication, but a con-
sequence of the density-dependent transition during
late life-stage in the mosquito.
It has been reported that AZM has schizontocidal
activity against P. falciparum [20], Plasmodium vivax
[23] and P. berghei [19], implying that AZM may reduce
transmission, to some extent, by killing progenitor cells
of gametocytes. Although available reports on gametocy-
tocidal effect of AZM against human malaria are lim-
ited, AZM has been reported to have a small impact on
reducing P. vivax gametocytes [41], but almost no
impact on P. falciparum gametocytaemia [42]. The latter
case is consistent with the observation that P. falci-
parum gametocytes are resistant to most schizontocidal
drugs [27]. In terms of gametocyte reducing activity, the
impact of AZM on P. berghei gametocytaemia would be
similar to that on P. falciparum, rather than P. vivax.I n
the present study, we focused on the activity of AZM
against mosquito stages of P. berghei, and demonstrated
that AZM reduces sporozoite burden in salivary glands,
independently of its gametocytocidal effect. Coleman
et al reported that several compounds which had shown
transmission-blocking activity against P. berghei were
also effective against both P. falciparum and P. vivax
[5,12], suggesting that P. berghei model would be useful
for screening of candidate compounds for a transmis-
sion-blocking drug for human malaria. Taken together,
AZM would be promising for suppressing mosquito
stage development of P. falciparum and P. vivax,a n d
would deserve further study.
In the present study, AZM treatment resulted in 79%
and 50% reduction in sporozoites in the midgut and
salivary glands, respectively, whereas prevalence of mos-
quitoes was not affected. Considering that inocula of
only 10 sporozoites in wide range of Plasmodium spp.
can be infectious to their vertebral hosts, the prevalence
rather than the infection intensity of mosquitoes would
be a suitable parameter for evaluating any transmission-
blocking strategy [40]. However, it has been proposed
by Medley et al [43] that the impact of transmission-
blocking substances appears mainly on reduction in
infection intensity, but noto nt h a to fp r e v a l e n c eu n d e r
conditions of high oocyst intensities, whereas a rapid
reduction in prevalence occurs under conditions of low
oocyst intensities. The authors claim that their data
derived from several Plasmodium spp. including P. falci-
parum and P. vivax, may afford broad applicability.
Their observations have been supported by Sinden et al
[40], who reported a saturating relationship between
mean oocyst numbers and mean salivary gland sporo-
zoite numbers, implying that the impact of 50% reduc-
tion in oocyst number becomes evident in reduction of
salivary gland sporozoite when oocyst burden is low
(less than 50 oocysts per mosquito). Furthermore, the
authors also demonstrated that a 90% blockade in
oocyst numbers gives no effect on prevalence of infected
mosquitoes when mean oocyst numbers are high (more
than 100), whereas significant reduction in prevalence is
expected when oocyst load is very low (less than 10).
Taking these information into account, the inhibitory
effect of AZM on P. berghei development in the mos-
quito observed under conditions of high parasite load
may allow to speculate that AZM would reduce both
infection intensity and prevalence of the mosquitoes
that fed blood from individuals carrying gametocytes of
human malaria parasites under field conditions where
parasite loads of P. falciparum or P. vivax are signifi-
cantly lower than those in this study [44-46]. In order
to examine that possibility, further studies on transmis-
sion blocking effect of AZM on P. berghei under condi-
tions of low parasite loads are underway.
The dose of AZM administered to mice in this study
(400 mg/kg) was much higher than those used for
human clinical practice (10-40 mg/kg) [17,19,35,47]. It
has been reported that there are significant interspecies
difference in pharmacokinetic parameters of AZM
b e t w e e nm i c ea n dh u m a n[ 4 8 - 5 0 ] .T h ed o s ea n dp e a k
concentration of AZM required for efficacy in murine
models are considerably greater than those in human
due to the higher rate of AZM clearance in mice (e.g.
much shorter half-life and greater clearance rate in mice
than in human) [48-50]. Therefore, the results obtained
by the murine model in this study do not suggest that
administration of 400 mg/kg of AZM would be neces-
sary for suppression of the mosquito stage development
of human malaria parasites.
The precise mechanism of the effect of AZM on api-
coplast replication has not been fully elucidated. Sidhu
et al [15] reported an intensive study using selected
AZM-resistant P. falciparum a n dp r o p o s e dt h a tt h e
anti-malarial properties of AZM are a result of its
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inhibiting protein synthesis in this organelle. Therefore,
it will be necessary to investigate the inhibitory effect of
AZM on the mosquito-stage development in genetically
modified P. berghei that have various mutations in the
genes coding for apicoplast ribosomal proteins. If bind-
ing of AZM to the apicoplast ribosomal protein leads to
inhibition of both apicoplast replication and sporogony
in the mosquito, it could be confirmed that the apico-
plast is the target of AZM.
Inhibitory mechanism of AZM on gametocyte-ookinete
transformation could not be explained by the suppression
of apicoplast replication, because apicoplast does not repli-
cate at this phase. A possible explanation would be that
AZM may block the fatty acid synthesis pathway within
the apicoplast, causing the parasite to run out of material
necessary for the drastic membrane biogenesis and reorga-
nisation to form machinery for motility and invasion, dur-
ing gametocyte-ookinete transformation [33].
Conclusions
It is a new finding that AZM reduces Plasmodium spor-
ozoite production in the mosquito, the mechanism of
which would not depend on gametocytocidal effect, but
be caused by suppression of apicoplast replication and
an uncharacterised effect on gametocyte-ookinete trans-
formation. In conclusion, clear advantages of AZM
i n c l u d e ;1 )au n i q u ef e a t u r eo fm u l t i - t a r g e t i n ga tb l o o d
stage (treatment), liver stage (prophylaxis), and mosquito
stage (transmission blocking), possibly by a common
mechanism of action including the inhibition of apico-
plast replication, and 2) an excellent safety profile that
allows AZM to be given to children and pregnant
women. Both of these advantages would warrant further
investigations of AZM, especially on its prevalence-redu-
cing efficacy under conditions of low parasite loads.
Thereafter, AZM would be tested for the substantial
transmission-blocking activity against human malaria
parasites, in the expectation of a new drug which would
be effective in reducing malaria morbidity and mortality
and inhibit the spread of drug-resistant parasites in
malaria endemic areas.
Additional file 1: Primer sets for Plasmodium berghei organelle-
specific genes
Click here for file
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